Impact of Immunoscore Colon Test on Adjuvant Therapeutic Strategy in Non-Metastatic Colon Cancer

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

February 28, 2021

Conditions
Colonic Neoplasms
Interventions
DIAGNOSTIC_TEST

Immunoscore Colon Test

Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.

Trial Locations (21)

13003

Hôpital Européen Marseille, Marseille

Unknown

Hôpital Simone Veil, Blois

Hospices civils de Colmar, Colmar

CHU de Dijon, Dijon

CHD de Vendée, La Roche-sur-Yon

Centre Oscar Lambret, Lille

CHU de Limoges, Limoges

Centre Léon Bérard, Lyon

Hôpital Jean Mermoz, Lyon

Institut Régional du Cancer de Montpellier, Montpellier

CHU Hôtel-Dieu, Nantes

Hôpital Saint-Louis, Paris

CHU de Bordeaux - Haut Lévêque, Pessac

CHU de Poitiers, Poitiers

Centre Hospitalier Annecy Genevois, Pringy

CHU de Reims, Reims

Centre Eugène Marquis, Rennes

Institut de Cancérologie de l'Ouest, Saint-Herblain

Hôpital du Léman, Thonon-les-Bains

Institut Gustave Roussy, Villejuif

Hôpital privé de Villeneuve d'Ascq, Villeneuve-d'Ascq

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

HalioDx

INDUSTRY

lead

UNICANCER

OTHER